ArticleFrontiers in neurology2024
Global, regional, and national time trends in the burden of epilepsy, 1990-2019: an age-period-cohort analysis for the global burden of disease 2019 study.
Article in Frontiers in neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- An updated estimate of the proportion of neurocysticercosis among people with epileptic seizures: a systematic review and Bayesian meta-analysis.Infectious diseases of poverty · 2026Pooled it
- Global trends in epilepsy and the Chinese experience: Epidemiological transitions, underlying mechanisms, and integrated strategies (1990-2021).Neuroprotection (Chichester, England) · 2026Review
- Long-Term Trends and Projections of the Global Epilepsy Burden: Insights From the Global Burden of Disease Study 2021.Health care science · 2026Article
- Design and Simulation of Lamotrigine Intermittent Release from a Subcutaneous Implant with an Enzymatic Biosensor Based on Clinical Data.Biosensors · 2026Article
- Article
- The impact of predator stress on electroshock seizure threshold: insights into GABAergic, glutamatergic, and serotonergic pathways in mice.Behavioral and brain functions : BBF · 2026Article
- Epidemiological Trends of Idiopathic Epilepsy in Asia: 1990-2021 - An Analysis from the Global Burden of Disease Study 2021.Neuroepidemiology · 2026Article
- Neuroprotective activity of thiolutin in epileptic mice: the inhibition of NLRP3 inflammasome.Human cell · 2025Article
- Global, regional, and national children and adolescent epilepsy burden, 1990-2021: an analysis based on the global burden of disease study 2021.Annals of medicine · 2025Article
- Prevalence of epilepsy and the epilepsy treatment gap in Bauchi, Northeast Nigeria: a cross-sectional study of two communities.BMJ open · 2025Article
- The Plasminogen Activation System in the Central Nervous System: Implications for Epilepsy and Neuropsychiatric Disorders.International journal of molecular sciences · 2025Review
- Global burden trends of idiopathic epilepsy in young adults from 1990 to 2035: based on the global burden of disease study 2021.BMC neurology · 2025Article
- Deep learning-based detection of generalized convulsive seizures using a wrist-worn accelerometer.Epilepsia · 2025Article
- Global, regional, and national burden of knee osteoarthritis: findings from the Global Burden of Disease study 2021 and projections to 2045.Journal of orthopaedic surgery and research · 2025Article
- L-quebrachitol Modulates the Anti-convulsant Effects of Carbamazepine Possibly Through Voltage-gated Sodium Channel Blocking Mechanism in Chicks: In Vivo and In Silico Studies.Brain and behavior · 2025Article
- Clinical and functional characterization of the GABRB3 p.Met80Val variant in early-onset epilepsy with long-term follow-up.Italian journal of pediatrics · 2025Article
- Global, regional, and national burden of epilepsy, 1990-2021: a systematic analysis for the Global Burden of Disease Study in 2021.Cost effectiveness and resource allocation : C/E · 2025Article
- Global, regional, and national burden of refraction disorders: findings from the global burden of disease study 2021 and projections to 2050.BMC public health · 2025Article
- Global burden of hypertensive heart disease attributable to high body mass index from 1990 to 2021: a multidimensional analysis and public health response.Frontiers in cardiovascular medicine · 2025Article
- Global, regional, and national epilepsy of unknown cause incidence and mortality, 1990-2036: cross-national health inequalities and predictive analytics.Frontiers in neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epilepsy is a non-communicable chronic brain disease that affects all age groups. There are approximately 50 million epilepsy patients worldwide, which is one of the most common neurological disorder. This study reports the time trends in the burden of epilepsy from 1999 to 2019. Methods: We evaluated the disease burden and its temporal trends of epilepsy using the prevalence and years lived with disability (YLDs), which was estimated based on the Global Burden of Disease (GBD) 2019 study. The age-period-cohort (APC) model was used to estimate the temporal trends of the epilepsy prevalence and YLDs rates, and to analyze the relative risks of age, periods and queues (age/period/queue effects). Results: In the past 30 years, the global age-standardized prevalence rate and age-standardized rate has increased by 29.61% and 27.02%, respectively. Globally, the APC model estimated the net drift of prevalence and YLDs were 0.88% (95% CI: 0.83-0.93) and 0.80% (95% CI: 0.75-0.85) per year. Among 204 countries and territories, the YLDs in 146 and prevalence 164 showed an increasing trend. And the risk of YLDs and prevalence increases with age, with the lowest risk among 0-4 years old and the highest risk among 75-79 years old. Unfavorable increasing period and cohort risks of YLDs and prevalence were observed. Conclusion: Over the past 30 years, the YLDs and prevalence of epilepsy have gradually increased globally and unfavorable increasing period and cohort risks were observed. Emphasizing epilepsy prevention, strengthening epilepsy health education, optimizing older adults epilepsy diagnosis and treatment plans, and actively promoting epilepsy diagnosis and treatment plans can effectively reduce new cases of epilepsy and related disabilities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.